Darbufelone is a dual inhibitor of cellular PGF2α and LTB4 production; it exhibits anti-inflammatory and anti-arthritic effects in animal models without causing gastric ulcers; it demonstrates anti-proliferative activity against non-small cell lung cancer (NSCLC) cell lines (A549, H520, and H460); it reduces tumor volume and weight in mice in a dose-dependent manner, with significant efficacy at 80 mg/kg/day.